Paul Calabresi Career Development Award for Clinical Oncology (K12)

Paul Calabresi 临床肿瘤学职业发展奖（K12）

• 批准号: 8873930
• 负责人: MARK H. EINSTEIN
• 金额: $ 8.34万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-29 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8873930
• 关键词: Advisory Committees; Albert Einstein Cancer Center; Clinical; Clinical Investigator; Clinical Oncology; Clinical Research; Clinical Trials; Development; Discipline; Discipline of obstetrics; Education; Educational Curriculum; Evaluation; Faculty; Funding; Grant; Gynecology; Institutes; Institution; Instruction; K-Series Research Career Programs; Leadership; Malignant Neoplasms; Medical; Medicine; Mentors; Participant; Pediatrics; Physicians; Principal Investigator; Process; Program Evaluation; Qualifying; Radiation; Recruitment Activity; Research; Research Methodology; Research Personnel; Research Project Grants; Rest; SECTM1 gene; Scientist; Series; Therapeutic; Therapeutic Human Experimentation; Training; Translational Research; base; career; college; design; experience; innovation; member; novel; oncology; patient oriented; professor; programs

 DESCRIPTION (provided by applicant): This is a competitive renewal application for the Paul Calabresi Career Development Award for Clinical Oncology (K12) funded and initiated in January 2010. The objective of the program is to provide a framework for the development of clinical and translational physician-scientists at the Albert Einstein College of Medicine. This ha been achieved through a coordinated program of mentoring, an established innovative series of formal courses, and research projects with an interdisciplinary, collaborative design. The program, its leadership and participants are integrated within the established research programs of the NCI-designated Albert Einstein Cancer Center (AECC) and Einstein's Institute for Clinical and Translational Research (ICTR); the latter focused on the training and mentoring of young clinical investigators. The Einstein Calabresi Program selects highly qualified clinical and translational investigators, primarily MDs but including some PhDs, that are committed to developing careers in patient-oriented clinical and translational research. The training focus is on cancer therapeutics. A formal curriculum has been developed in conjunction with Einstein's ICTR (funded in part by a CTSA grant) featuring an MS degree in Clinical Research Methods and a new course on "Clinical Trial Development in the Era of Personalized Cancer Medicine" along with individualized instruction based on the background and needs of each Scholar. The leadership of the program brings together senior Einstein faculty with strong backgrounds in cancer therapeutics research, postgraduate training in the clinical oncology disciplines, and clinical research methods. The Principal Investigators are Dr. Roman Perez-Soler, Professor of Medicine, Deputy Director of the AECC, and co-director of AECC's Experimental Therapeutics Program and Dr. Mark Einstein, Professor and Vice-Chair for Research in the Department of Obstetrics & Gynecology. Both PI's have an established track-record of translational research in cancer therapeutics as well as mentoring junior clinical investigators. The Educational Coordinator, Dr. Paul Marantz, is Associate Dean for Clinical Research Education and Associate Director of Einstein's ICTR. He is an innovator in the development of educational programs in clinical research methods for physicians and is co-PI of Einstein's CTSA. Novel initiatives are planned including training for mentors and processes for the external evaluation of the program. An Advisory Committee of AECC's senior faculty leaders provide oversight in the selection and ongoing evaluation of the progress of Calabresi Scholars and the impact of the program. The leadership is assisted by an External Advisory Committee with members experienced in directing Calabresi programs at other institutions. Over the first four years of funding, fourteen Scholars were recruited to the program from medical-, pediatrics-, radiation- and gynecological- oncology. Two Scholars were PhDs, the rest MDs or MD/PhDs. Nine Scholars will have completed the program by the end of the current period of support, all pursuing successful careers at major academic centers, six at Einstein.

 描述（由申请人提供）：这是一项针对临床肿瘤学 Paul Calabresi 职业发展奖 (K12) 的竞争性续展申请，于 2010 年 1 月资助并启动。该计划的目标是为临床和转化的发展提供一个框架。阿尔伯特·爱因斯坦医学院的医师科学家们通过协调的指导计划、一系列既定的创新正式课程以及跨学科、协作设计的研究项目来实现这一目标。其领导层和参与者融入了 NCI 指定的阿尔伯特·爱因斯坦癌症中心 (AECC) 和爱因斯坦临床与转化研究所 (ICTR) 的既定研究项目；后者专注于年轻临床研究人员的培训和指导。 Calabresi 项目选择高素质的临床和转化研究人员，主要是医学博士，但也包括一些博士，他们致力于发展以患者为导向的临床和转化研究职业，培训重点是癌症治疗。与爱因斯坦 ICTR（部分由 CTSA 拨款资助）共同开发，具有临床研究方法硕士学位和“个性化癌症医学时代的临床试验开发”新课程以及基于背景的个性化指导该项目的领导者汇集了在癌症治疗研究、临床肿瘤学学科研究生培训和临床研究方法方面具有深厚背景的高级爱因斯坦教师，首席研究员是罗曼博士。 AECC 医学教授、副主任兼 AECC 实验治疗项目联席主任 Perez-Soler 和妇产科教授兼研究副主席 Mark Einstein 博士两位 PI 都有既定的发展方向。 - 癌症治疗转化研究以及指导初级临床研究人员的记录 教育协调员 Paul Marantz 博士是负责临床研究教育的副院长和助理。爱因斯坦卢旺达问题国际法庭主任。他是医生临床研究方法教育项目开发的创新者，也是爱因斯坦 CTSA 的联合 PI。计划中的新举措包括导师培训和外部评估流程。 该项目由 AECC 高级教师领导组成的咨询委员会负责监督 Calabresi 学者的选拔和持续评估以及该项目的影响。外部咨询委员会的成员在指导其他 Calabresi 项目方面经验丰富。在资助的前四年中，该项目招募了 14 名学者，其中两名学者是博士学位，其余是医学博士或医学博士。九名博士/博士将在当前支持期结束时完成该计划，他们都在主要学术中心追求成功的职业生涯，其中六名在爱因斯坦。